Form 4: Inogen Executive Stanislav Glezer Reports Stock Transactions
SEC Form 4 Filing
Stanislav Glezer, EVP, R&D & Chief Medical Officer of Inogen Inc., reports the acquisition and disposal of Inogen common stock and restricted stock units on March 1, 2024.
Summary
- On March 1, 2024, Stanislav Glezer, EVP, R&D & Chief Medical Officer of Inogen Inc., engaged in transactions involving Inogen's common stock and restricted stock units.
- Glezer acquired 13,914 shares of common stock through the vesting of restricted stock units.
- He disposed of 7,623 shares to cover tax withholding liabilities at a price of $7.025 per share.
- Following these transactions, Glezer directly owns 16,106 shares of common stock.
- He also acquired 43,993 restricted stock units, bringing his total holdings to 43,993 restricted stock units.
- The restricted stock units vest over time, contingent upon continued service.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive, indicating a neutral sentiment.
Future Outlook
The reported restricted stock units vest over time, contingent upon the reporting person's continued service with Inogen.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in beneficial ownership by a company executive.
- Employees may be impacted by the vesting schedule of the restricted stock units.
Key Dates
| Date | Description |
|---|---|
| 09/01/2022 | 25% of certain restricted stock units vest, followed by 1/16th every three months thereafter. |
| 03/01/2023 | 1/3rd of certain restricted stock units vest, followed by 1/3rd annually thereafter. |
| 03/01/2024 | Date of reported transactions: acquisition and disposal of common stock and restricted stock units; 1/3rd of certain restricted stock units vest, followed by 1/3rd annually thereafter. |
| 03/01/2025 | 1/3rd of certain restricted stock units vest, followed by 1/3rd annually thereafter. |
| 03/05/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.